Evaluation of Mobile Education Program in Patients With Atrial Fibrillation.
The Effect Of A Mobıle Educatıon Program and Telephone Follow-Up On Knowledge Level, Symptom Management And Qualıty Of Lıfe In Patıents Wıth Atrıal Fıbrıllatıon
1 other identifier
interventional
70
1 country
1
Brief Summary
This study was conducted to determine the effect of a mobile education program and telephone follow-up on the knowledge level, symptom management and quality of life of patients with atrial fibrillation. The study aims to answer the following questions.
- 1.Does the mobile education program and telephone follow-up have an effect on increasing the level of knowledge in patients with AF in the intervention group compared to the control group?
- 2.Does the mobile education program and telephone follow-up have an effect on reducing symptom severity in patients with AF in the intervention group compared to the control group?
- 3.Does the mobile education program and telephone follow-up have an effect on improving the quality of life in patients with AF in the intervention group compared to the control group?
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 27, 2025
CompletedStudy Start
First participant enrolled
June 1, 2025
CompletedFirst Posted
Study publicly available on registry
June 22, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2025
CompletedJune 22, 2025
June 1, 2025
1 month
May 27, 2025
June 12, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
The Jessa Atrial Fibrillation Knowledge Questionnaire
-The Jessa Atrial Fibrillation Knowledge Questionnaire- will be used to assess participants' knowledge about their AAF condition. The scale consists of a total of 16 items and 3 sub-dimensions. The lowest score to be obtained from the scale is "0" and the highest score is "16". The higher the score obtained from the scale, the higher the patient's level of knowledge.
The measurement will be done at the beginning of the study (day 0) and at the end of the 12th week.
The University of Toronto Atrial Fibrillation Severity Scale
The University of Toronto Atrial Fibrillation Severity Scale is a scale that will be used to assess the severity of AF-specific disease, the burden it creates in individuals and the frequency of AF episodes. The scale consists of 19 items and 3 sections. Higher scores indicate greater AF burden and more severe symptoms.
The measurement will be done at the beginning of the study (day 0) and at the end of the 12th week.
Effect of Atrial Fibrillation on Quality of Life Scale
Effect of Atrial Fibrillation on Quality of Life Scale consists of four sub dimensions and 20 questions measuring the quality of life of patients with AF. Scoring of the scale ranges from 0 to 100 in general and sub-dimension scores. A score of zero indicates that quality of life is negatively affected.
The measurement will be done at the beginning of the study (day 0) and at the end of the 12th week.
Secondary Outcomes (1)
System Usability Scale-SUS
Measurement will be done at the end of the study (at the end of the 12th week).
Study Arms (2)
Intervention Group
EXPERIMENTALControl Group
PLACEBO COMPARATORInterventions
Patient Information Form, Atrial Fibrillation Information Scale, Atrial Fibrillation Severity Scale and Atrial Fibrillation Impact on Quality of Life Questionnaire will be administered face-to-face by the researcher using Mobile Atrial Fibrillation Education Program (M-AFEP). The application link, individual e-mail and user passwords will be sent to the mobile phones of the participants and the application will be added to the main screens by entering the relevant address from their phones. Participants will be asked to use M-AFEP for twelve weeks / at least ten minutes a week and the frequency and duration of use will be recorded on the mobile application. Participants in the intervention group will be followed up by phone once a week in the first, fourth and eighth weeks and a reminder message (sms) will be sent for the use of M-AFEP. At the end of the twelfth week, the scales will be filled in again through the application.
* Participants in the control group will be given M-AFEP application usage training by the researchers. * The application link, individual e-mail and user passwords will be sent to the mobile phones of the participants in the control group. * Participants in the control group will enter the relevant address of the mobile application from their phones and the application will be added to their home screens. * In the M-AFEP application of the participants in the control group, there will be a short general information section containing information specific to AF, different from the intervention group content. Participants in the control group will continue only routine outpatient follow-up throughout the process and no intervention will be applied.
Eligibility Criteria
You may qualify if:
- years of age or older.
- Being literate.
- Atrial Fibrillation diagnosis.
- No cognitive and communication disabilities.
- Not having a diagnosed psychiatric illness.
- Ability to use technological devices.
- Having and using a smart phone with Android operating system and internet access.
- Acceptance to participate in the study.
You may not qualify if:
- Diagnosis of rheumatic valve disease, moderate/severe mitral stenosis and previous valve surgery.
- Functional class III or IV according to the New York Heart Association (NYHA) classification.
- Patients with existing or planned pacemaker, ICD (Implantable Cardioverter Defibrillator) and patients with existing or planned Radiofrequency Ablation treatment will not be included in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Akdeniz University Hospital Cardiology Polyclinic
Antalya, Konyaaltı, 07070, Turkey (Türkiye)
Related Publications (9)
Allan KS, Aves T, Henry S, Banfield L, Victor JC, Dorian P, Healey JS, Andrade JG, Carroll SL, McGillion MH. Health-Related Quality of Life in Patients With Atrial Fibrillation Treated With Catheter Ablation or Antiarrhythmic Drug Therapy: A Systematic Review and Meta-analysis. CJC Open. 2020 Apr 2;2(4):286-295. doi: 10.1016/j.cjco.2020.03.013. eCollection 2020 Jul.
PMID: 32695978BACKGROUNDGuo Y, Chen Y, Lane DA, Liu L, Wang Y, Lip GYH. Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial. Am J Med. 2017 Dec;130(12):1388-1396.e6. doi: 10.1016/j.amjmed.2017.07.003. Epub 2017 Aug 26.
PMID: 28847546BACKGROUNDSmigorowsky MJ, Norris CM, McMurtry MS, Tsuyuki RT. Measuring the effect of nurse practitioner (NP)-led care on health-related quality of life in adult patients with atrial fibrillation: study protocol for a randomized controlled trial. Trials. 2017 Aug 3;18(1):364. doi: 10.1186/s13063-017-2111-4.
PMID: 28774317BACKGROUNDPalm P, Qvist I, Rasmussen TB, Christensen SW, Hakonsen SJ, Risom SS. Educational interventions to improve outcomes in patients with atrial fibrillation-a systematic review. Int J Clin Pract. 2020 Nov;74(11):e13629. doi: 10.1111/ijcp.13629. Epub 2020 Sep 7.
PMID: 32726511BACKGROUNDPearsons A, Hanson CL, Gallagher R, O'Carroll RE, Khonsari S, Hanley J, Strachan FE, Mills NL, Quinn TJ, McKinstry B, McHale S, Stewart S, Zhang M, O'Connor S, Neubeck L. Atrial fibrillation self-management: a mobile telephone app scoping review and content analysis. Eur J Cardiovasc Nurs. 2021 May 22;20(4):305-314. doi: 10.1093/eurjcn/zvaa014.
PMID: 33620473BACKGROUNDWillems S, Borof K, Brandes A, Breithardt G, Camm AJ, Crijns HJGM, Eckardt L, Gessler N, Goette A, Haegeli LM, Heidbuchel H, Kautzner J, Ng GA, Schnabel RB, Suling A, Szumowski L, Themistoclakis S, Vardas P, van Gelder IC, Wegscheider K, Kirchhof P. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J. 2022 Mar 21;43(12):1219-1230. doi: 10.1093/eurheartj/ehab593.
PMID: 34447995BACKGROUNDJoglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Epub 2023 Nov 30.
PMID: 38033089BACKGROUNDBoriani G, Vitolo M, Diemberger I, Proietti M, Valenti AC, Malavasi VL, Lip GYH. Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes. Cardiovasc Res. 2021 Jun 16;117(7):1-21. doi: 10.1093/cvr/cvab147.
PMID: 33913486BACKGROUNDVan Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Lochen ML, Lumbers RT, Maesen B, Molgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176. No abstract available.
PMID: 39210723BACKGROUND
Related Links
- In the study, the educational content of the application developed for participants diagnosed with Atrial Fibrillation (M-AFEP, Mobile-Atrial Fibrillation Education Program) was used as a resource in the creation of the content.
- In the study, the educational content of the application developed for participants diagnosed with Atrial Fibrillation (M-AFEP, Mobile-Atrial Fibrillation Education Program) was used as a resource in the creation of the content.
- In the study, the educational content of the application developed for participants diagnosed with Atrial Fibrillation (M-AFEP, Mobile-Atrial Fibrillation Education Program) was used as a resource in the creation of the content.
- In the study, the educational content of the application developed for participants diagnosed with Atrial Fibrillation (M-AFEP, Mobile-Atrial Fibrillation Education Program) was used as a resource in the creation of the content.
- In the study, the educational content of the application developed for participants diagnosed with Atrial Fibrillation (M-AFEP, Mobile-Atrial Fibrillation Education Program) was used as a resource in the creation of the content.
- In the study, the educational content of the application developed for participants diagnosed with Atrial Fibrillation (M-AFEP, Mobile-Atrial Fibrillation Education Program) was used as a resource in the creation of the content.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer
Study Record Dates
First Submitted
May 27, 2025
First Posted
June 22, 2025
Study Start
June 1, 2025
Primary Completion
July 1, 2025
Study Completion
August 1, 2025
Last Updated
June 22, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share